Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.

Human psychopharmacology - 1 Jul 2004

Vandel P, Haffen E, Nezelof S, Broly F, Kantelip J P, Sechter D

Abstract excerpt

Cytochrome P450-2D6 may be involved in the metabolism of many drugs such as psychotropic drugs and its genetic polymorphism is responsible for inter-individual differences in the therapeutic effect and toxicity of these drugs. Moreover with the same genetic basis, CYP2D6 metabolic capacity variations are observed. Different factors of variation may be involved, among them the prescribed drugs. The aim of this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged
Share to Antidepressive Agents, Second-Generation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antidepressive Agents, Tricyclic

Share to Cytochrome P-450 CYP2D6

Share to Depressive Disorder

Share to Fluoxetine

Share to Genotype

Source

Identifiers

PMID: 15252821
DOI: 10.1002/hup.598

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.PMID 15252821Read ↗

Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics.Semantic proximity Read ↗

Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.Semantic proximity Read ↗

Antidepressant drugs in the elderly--role of the cytochrome P450 2D6.Semantic proximity Read ↗

Identification of CYP2D6 allelic mutations in a sub-set of Karachi populationSemantic proximity Read ↗

Identification of CYP2D6 allelic mutations in a sub-set of Karachi populationSemantic proximity Read ↗

The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.Semantic proximity Read ↗

Pharmacogenetics of antidepressants: clinical aspects.Semantic proximity Read ↗

Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.Semantic proximity Read ↗

Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes.Semantic proximity Read ↗

CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.Semantic proximity Read ↗

Pharmacogenetics and drug metabolism of newer antidepressant agents.Semantic proximity Read ↗

Evaluation of cytochrome P450 2D6 phenotyping in healthy adult Western Indians.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.